The trial will test 10,000 scans at up to 15 hospitals across the country and will be rolled out nationally if successful.

By targeting a newly uncovered weakness in prostate cancer cells, this could offer an improved treatment for the disease.

Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma To our knowledge, no ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

Watch parts 1, 2, and 3 of our conversation with Dr Collins.

Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma Authors retain all rights ...

Prostate cancer is one of the most common cancers affecting men in the United States, and it comes with a heavy price tag. Nearly 300,000 men are expected to be diagnosed this year, and treatment ...

A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

Talk a walk through Park Tool's HQ factory with CEO Eric Hawkins to see how they make and test their tools in and around ...

AI is showing up in the strangest of places. People use it for seemingly everything, from asking embarrassing questions to building entire businesses. They're using it to create content, get help with ...

Google now has three AI CLIs for different workflows. Gemini CLI handles fast, interactive coding in the terminal. Jules Tools brings cloud autonomy into command-line control. Last week, Google ...